Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754311 | 0.85 | KDM5A (0.30) | KDM5AKDM4C | |
| SCHEMBL25754307 | 0.79 | NR1I2 (0.32) | ZDHHC20 | |
| SCHEMBL25754340 | 0.75 | ZDHHC20 (0.35) | ZDHHC20 | |
| SCHEMBL25754203 | 0.75 | CES2 (0.47) | MEN1KMT2AZDHHC20 | |
| SCHEMBL25444922 | 0.73 | MEN1 (0.53) | KDM5AKDM4CDNM1MEN1KMT2A | |
| SCHEMBL25754328 | 0.72 | ZDHHC20 (0.32) | ZDHHC20 | |
| SCHEMBL25754268 | 0.70 | HTR1D (0.32) | — | |
| SCHEMBL24061839 | 0.70 | HTR1D (0.38) | MEN1KMT2A | |
| SCHEMBL25793843 | 0.70 | KDM5A (0.37) | KDM5AKDM4CDNM1MEN1KMT2A | |
| SCHEMBL20231425 | 0.69 | CES2 (0.48) | KDM5AKDM4CDNM1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | KDM5A 2426/4885KDM4C 2021/4885DNM1 2980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.